Ipilimumab 200mg/40ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Cytotoxic drugs
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ipilimumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ipilimumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Ipilimumab on the MHRA register
Yervoy 200mg/40ml concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Ipilimumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(15)
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)
Melanoma: assessment and management (NG14)
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
14.7 days
Mechanism
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that compete…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
65.8µg/mL
[L12126]
Data regarding the AUC and Tmax of ipilumumab are not readily available.
[A35118][L12126]
Half-life
14.7 days
[A35118]
Protein binding
[L12126]
Volume of distribution
7.21L
[A35118]
Metabolism
[L12126][L12642]…
Elimination
[L12126]
Clearance
15.3 mL
[A35118]
Systemic clearance increases proportionally with body weight.
[L12642]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Ipilimumab was granted FDA approval on 25 March 2011.[L12126]
Melanoma
- Treatment of unresectable or metastatic melanoma in adult and pediatric patients ≥12 years old, alone or in combination with [nivolumab]
- Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of >1 mm who have undergone complete resection, including total lymphadenectomy
Renal Cell Carcinoma (RCC)
- First-line treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma in combination with nivolumab
Colorectal Cancer
- In combination with nivolumab, treatment of patients ≥12 years old with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer
Hepatocellular Carcinoma
- In combination with nivolumab, first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma
- In combination with nivolumab, treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib
Non-Small Cell Lung Cancer (NSCLC)
- Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1, with no EFGR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab
- Treatment of adult patients with metastatic or recurrent non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy
Malignant Pleural Mesothelioma
- Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1134 interactions
[L12126]
However, the most common adverse reactions to ipilumumab are fatigue, diarrhea, pruritus, rash, and colitis.
[L12126]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L12126]
Data regarding the AUC and Tmax of ipilumumab are not readily available.
[A35118][L12126]
[A35118]
[L12126]
[A35118]
[L12126][L12642]
Because ipilimumab is a protein, it is expected to be degraded into small peptides and amino acids by proteolytic enzymes.
[A35122]
[L12126]
[A35118]
Systemic clearance increases proportionally with body weight.
[L12642]
Proteins and enzymes this drug interacts with in the body
ATC L01FX04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ipilimumab
Additional database identifiers
Drugs Product Database (DPD)
21164
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2505
GenAtlas
CTLA4
GeneCards
CTLA4
GenBank Gene Database
AF411058
GenBank Protein Database
17646228
Guide to Pharmacology
2743
UniProt Accession
CTLA4_HUMAN
Patent information
All patents expired, 1 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: